184 related articles for article (PubMed ID: 28128737)
1. TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level.
Malik SA; Khan MS; Dar M; Hussain MU; Mudassar S
Cancer Biomark; 2017; 18(4):389-395. PubMed ID: 28128737
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
3. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
[TBL] [Abstract][Full Text] [Related]
4. High expression of TAZ indicates a poor prognosis in retinoblastoma.
Zhang Y; Xue C; Cui H; Huang Z
Diagn Pathol; 2015 Oct; 10():187. PubMed ID: 26464030
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis.
Wei Z; Wang Y; Li Z; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Wu Y; Cheng J
J Oral Pathol Med; 2013 Nov; 42(10):747-54. PubMed ID: 23551691
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.
Malik SA; Khan MS; Dar M; Hussain MU; Shah MA; Shafi SM; Mudassar S
Pathol Oncol Res; 2018 Apr; 24(2):207-214. PubMed ID: 28434174
[TBL] [Abstract][Full Text] [Related]
8. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Yang H; Gao XY; Li P; Jiang TS
Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
[TBL] [Abstract][Full Text] [Related]
9. Raf1 is a prognostic factor for progression in patients with non‑small cell lung cancer after radiotherapy.
Tian H; Yin L; Ding K; Xia YY; Wang XH; Wu JZ; He X
Oncol Rep; 2018 Apr; 39(4):1966-1974. PubMed ID: 29484414
[TBL] [Abstract][Full Text] [Related]
10. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
11. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed C14orf166 associates with disease progression and poor prognosis in non-small-cell lung cancer.
Zhou YW; Li R; Duan CJ; Gao Y; Cheng YD; Zhang CF
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30126850
[TBL] [Abstract][Full Text] [Related]
13. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
Bai Y; Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Zhao BS
Int J Clin Exp Pathol; 2015; 8(1):824-9. PubMed ID: 25755781
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
15. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
16. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
17. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer.
Noguchi S; Saito A; Horie M; Mikami Y; Suzuki HI; Morishita Y; Ohshima M; Abiko Y; Mattsson JS; König H; Lohr M; Edlund K; Botling J; Micke P; Nagase T
Clin Cancer Res; 2014 Sep; 20(17):4660-72. PubMed ID: 24951773
[TBL] [Abstract][Full Text] [Related]
18. Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer.
Sun J; Che SL; Piao JJ; Xu M; Chen LY; Lin ZH
Tumour Biol; 2017 Mar; 39(3):1010428317695918. PubMed ID: 28349826
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value.
Yao JT; Zhao SH; Liu QP; Lv MQ; Zhou DX; Liao ZJ; Nan KJ
Pathol Res Pract; 2017 May; 213(5):453-456. PubMed ID: 28343871
[TBL] [Abstract][Full Text] [Related]
20. Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer.
Zhao Z; Zheng N; Wang L; Hou Y; Zhou X; Wang Z
Oncotarget; 2017 Jan; 8(5):7827-7838. PubMed ID: 27999199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
